InvestSMART

Percheron Therapeutics Limited (ASX: PER) - Announcements

- Current share price for PER : $0.004

ASX company news and announcements for Percheron Therapeutics Limited (PER) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Percheron Therapeutics Limited (PER) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Percheron Therapeutics Limited (PER), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Percheron Therapeutics Limited (PER)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$7 Prospectus - Non-renounceable Entitlement Offer 16 Mar 2026 10:01AM $0.007 $0.004 fallen by 42.86%
$7 Non-renounceable Entitlement Offer 16 Mar 2026 9:59AM $0.006 $0.004 fallen by 33.33%
$7 Proposed issue of securities - PER 13 Mar 2026 6:22PM $0.006 $0.004 fallen by 33.33%
$7 Half Yearly Report and Accounts 26 Feb 2026 12:41PM $0.007 $0.004 fallen by 42.86%
$7 Percheron to Present at the 2026 AACR Annual Meeting 19 Feb 2026 8:09AM $0.007 $0.004 fallen by 42.86%
$7 Percheron Therapeutics Limited - Corporate Presentation 18 Feb 2026 8:15AM $0.007 $0.004 fallen by 42.86%
$7 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 8:46AM $0.008 $0.004 fallen by 50%
$7 Change of Director's Interest Notice - Dr Ben Gil Price 30 Dec 2025 9:16AM $0.009 $0.004 fallen by 55.56%
$7 Change of Director's Interest Notice - Dr James Garner 23 Dec 2025 9:57AM $0.009 $0.004 fallen by 55.56%
$7 Percheron Therapeutics Limited Corporate Presentation 5 Nov 2025 8:37AM $0.008 $0.004 fallen by 50%
$7 Quarterly Activities Report and Appendix 4C 31 Oct 2025 8:57AM $0.008 $0.004 fallen by 50%
$7 Results of Annual General Meeting 22 Oct 2025 12:47PM $0.009 $0.004 fallen by 55.56%
$7 Annual General Meeting - Management Presentation 22 Oct 2025 9:47AM $0.009 $0.004 fallen by 55.56%
$7 Annual General Meeting - Chair's Address 22 Oct 2025 9:45AM $0.009 $0.004 fallen by 55.56%
$7 HMBD-002 Phase I Clinical Trial - Webinar Presentation 7 Oct 2025 8:23AM $0.011 $0.004 fallen by 63.64%
$7 HMBD-002 Phase I Trial Results 7 Oct 2025 8:22AM $0.011 $0.004 fallen by 63.64%
$7 Progress Update on HMBD-002 Development 30 Sep 2025 8:20AM $0.009 $0.004 fallen by 55.56%
$7 Chief Medical Officer and Chief Technology Officer Appointed 23 Sep 2025 12:15PM $0.010 $0.004 fallen by 60%
$7 2025 Notice of Annual General Meeting 22 Sep 2025 8:26AM $0.010 $0.004 fallen by 60%
$7 Percheron Receives $1.43m R&D Tax Incentive Rebate 29 Aug 2025 9:08AM $0.011 $0.004 fallen by 63.64%
$7 Notice of date of AGM and other relevant dates 28 Aug 2025 1:41PM $0.011 $0.004 fallen by 63.64%
$7 Appendix 4G and Corporate Governance Statement 28 Aug 2025 1:36PM $0.011 $0.004 fallen by 63.64%
$7 Appendix 4E and Annual Report 28 Aug 2025 1:33PM $0.011 $0.004 fallen by 63.64%
$7 New Preclinical Data Reported for HMBD-002 in Breast Cancer 6 Aug 2025 8:17AM $0.008 $0.004 fallen by 50%
$7 Quarterly Activities Report and Appendix 4C 31 Jul 2025 8:20AM $0.009 $0.004 fallen by 55.56%

51 - 75 of 200 results

Page 3 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.